Question explored with the scientific record
Side effects emprazole
The short version: emprazole (omeprazole) is linked to serious but uncommon side effects including magnesium deficiency, kidney injury, severe allergic reactions, and gut infections. The evidence is mostly case reports and observational studies, not large controlled trials.
The most documented risk is magnesium depletion. Multiple case reports show long-term omeprazole use can cause dangerously low magnesium, leading to muscle spasms, abnormal heart rhythms, and low calcium and potassium levels [1, 7, 8]. One patient's magnesium dropped to 0.29 mmol/L (normal ~0.75-1.0) and only recovered after stopping omeprazole [8]. A meta-analysis of observational studies found PPI users had a 43% higher odds of hypomagnesemia [9]. The mechanism appears to involve altered gut bacteria that impair magnesium absorption in the colon [10].
Kidney damage is another established risk. A study of 20 patients with omeprazole-induced acute interstitial nephritis found creatinine levels spiking from ~90 to as high as 1,400 µmol/L [3]. Observational data shows a 2.5-fold increased risk of acute kidney injury and 3-fold risk of acute interstitial nephritis with PPI use [9].
| Side effect | Risk estimate | Evidence type |
|---|---|---|
| Hypomagnesemia | OR 1.43 (1.08-1.88) | Meta-analysis of observational studies [9] |
| Acute kidney injury | OR 2.52 (2.27-2.79) | Observational [9] |
| Acute interstitial nephritis | OR 3.0 (1.47-6.14) | Observational [9] |
| Clostridium difficile infection | OR 1.74 (1.47-2.85) | Meta-analysis [9] |
| Bone fracture | OR 1.33 (1.15-1.54) | Meta-analysis [9] |
Allergic reactions range from skin rashes to life-threatening anaphylaxis. Two case reports describe patients with omeprazole-induced anaphylaxis presenting with dizziness, difficulty breathing, and dangerously low blood pressure [6]. A severe reaction called DRESS syndrome (fever, rash, organ inflammation) has also been documented [4]. Cross-reactivity between different PPIs is common [2, 5].
The evidence has serious limitations. Most comes from case reports and observational studies, not randomized trials. The JAMA editorial notes these risks are based on "low-grade evidence" and may be influenced by the underlying health conditions that lead people to take PPIs [9]. A 2025 meta-analysis of randomized trials found no significant increase in C. difficile infection with PPIs (RR 1.19, 0.75-1.89) [11], contradicting the observational data.
My call: omeprazole carries real, documented risks of magnesium depletion, kidney injury, and severe allergic reactions. The benefits for short-term acid suppression are well-established, but long-term use requires careful justification and monitoring. Confidence: moderate - the risks are real but their exact frequency is uncertain due to poor-quality evidence.
Sources used 11
-
Functional hypoparathyroidism secondary to magnesium deficiency in long-term users of proton pump inhibitor
A long-term omeprazole user with severe hypomagnesemia had functional hypoparathyroidism and hypocalcemia; magnesium replacement normalized PTH and electrolytes, and omeprazole rechallenge reproduced hypomagnesemia, supporting PPI-induced magnesium deficiency as the cause.
DOI: 10.14341/osteo20173102-107 -
Hypersensitivity Reactions to Taxanes and Platins
A multi-paper report describing hypersensitivity reactions to proton pump inhibitors (PPI) with cross-reactivity patterns and desensitization approaches for taxanes/platinum-based chemotherapies, including oxaliplatin, across three single-center studies.
DOI: 10.1016/j.jaci.2012.12.1251 -
Omeprazole‐induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype
This study investigates the relationship between CYP2C19 genotype and phenotype in patients with omeprazole-induced acute interstitial nephritis, finding no significant association between the genotype and the occurrence of this adverse reaction.
DOI: 10.1111/j.1365-2125.2010.03623.x -
Omeprazole-induced drug reaction with eosinophilia and systemic symptoms (DRESS)
This study reports on a case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) following omeprazole treatment in an 88-year-old woman, highlighting the clinical features and diagnostic challenges associated with this severe drug reaction.
DOI: 10.1684/ejd.2014.2343 -
Proton Pump Inhibitor-Induced Neutropenia
This case report describes a 60-year-old man who experienced neutropenia associated with omeprazole treatment, which recurred upon switching to pantoprazole, suggesting possible cross-reactivity between these proton pump inhibitors.
DOI: 10.2165/11537230-000000000-00000 -
Lessons from two cases of anaphylaxis to proton pump inhibitors
This study presents two cases of anaphylaxis associated with proton pump inhibitors (PPIs), specifically lansoprazole and omeprazole, highlighting the need for increased awareness among physicians regarding hypersensitivity reactions to these medications.
DOI: 10.1111/j.1365-2710.2012.01348.x -
Severe acute neurological symptoms related to proton pump inhibitors induced hypomagnesemia responsible for profound hypoparathyroidism with hypocalcemia
This study presents two cases of severe neurological symptoms in patients induced by hypomagnesemia due to long-term use of proton pump inhibitors (PPIs), highlighting the need for awareness of this potential adverse effect.
DOI: 10.1016/j.clinre.2014.03.005 -
Severe hypomagnesemia refractory to oral supplementation associated to omeprazole treatment
This study reports a case of severe hypomagnesemia in a patient undergoing long-term omeprazole treatment, highlighting the potential for proton pump inhibitors to cause magnesium deficiency that is refractory to oral supplementation.
DOI: 10.1016/j.endoen.2012.08.005 -
Adverse Effects Associated With Proton Pump Inhibitors
This JAMA Internal Medicine editorial synthesizes recent observational evidence on adverse effects associated with proton pump inhibitor use, highlighting risks of chronic kidney disease, hypomagnesemia, Clostridium difficile infection, pneumonia, and fractures, and urging cauti…
DOI: 10.1001/jamainternmed.2015.7927 -
Low gut microbiota diversity and dietary magnesium intake are associated with the development of PPI‐induced hypomagnesemia
In a controlled mouse study, omeprazole treatment reduces serum magnesium under a low dietary Mg2+ condition, alters gut microbiota diversity and composition (notably increasing Lactobacillus and Bifidobacterium), and low Mg2+ intake increases colonic formate, collectively linki…
DOI: 10.1096/fj.201900839R -
Proton pump inhibitors are not associated with an increased risk of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials
This is a comprehensive PRISMA-guided meta-analysis of randomized controlled trials that finds proton pump inhibitors (PPIs) do not significantly increase the risk of Clostridioides difficile infection (CDI) compared with placebo or several acid-suppressive comparators in adults…
DOI: 10.1080/19490976.2025.2562341